Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: A pharmacokinetic and pharmacodynamic investigation

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 2, 2005, Pages 155-161

  Cleland, John G F ^a   Sullivan, John T ^b   Ball, Stephen ^c   Horowitz, John D ^d   Agoram, Balaji ^b   Rosser, Dylan ^b   Yates, Wayne ^b   Tin, Lwin ^a   Fuentealba, Paulina ^c   Burton, Paul B J ^b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b AMGEN INC   (United States)

^c Academic Unit of Cardiovascular Medicine   (United Kingdom)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Anemia; Heart failure; Hemoglobin; Pharmacokinetics; Risk factors

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BREATHING DISORDER; CAPILLARY RESISTANCE; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEEP VEIN THROMBOSIS; DISEASE EXACERBATION; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HEART FAILURE; HEART INFARCTION; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; INFORMED CONSENT; INJECTION SITE; LUNG EMBOLISM; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT;

AGED; ANEMIA; BIOLOGICAL AVAILABILITY; CARDIAC OUTPUT, LOW; CHRONIC DISEASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED;

EID: 23044433928     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000167013.77092.c4     Document Type: Article

References (26)

1. Horwich TB, Fonarow GC, Hamilton MA, et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. 2002;39:1780-1786.
2. Kalra PR, Bolger AP, Francis DP, et al. Effect of anemia on exercise tolerance in chronic heart failure in men. Am J Cardiol. 2003;91:888-891.
3. Szachniewicz J, Petruk-Kowalczyk J, Majda J, et al. Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. Int J Cardiol. 2003;90:303-308.
4. Silverberg DS, Wexler D, Slum M, et al. The use of subcutaneous erythropoetin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35:1737-1744.
5. Anand I, McMurray JJV, Whitmore J, et al. Anemia and its relationship to clinical outcome in heart failure. Circulation. 2004;110:149-154.
6. Sharma R, Francis DP, Pitt B, et al. Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J. 2004;25:1021-1028.
7. Felker GM, Gattis WA, Leimberger JD, et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol. 2003;92:625-628.
8. Kosiborod M, Smith GL, Radford MJ, et al. The prognostic importance of anemia in patients with heart failure. Am J Med. 2003;114:112-119.
9. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure. J Am Coll Cardiol. 2003;41:1933-1939.
10. Brucks S, Little WC, Chao T, et al. Relation of anemia to diastolic heart failure and the effect on outcome. Am J Cardiol. 2004;93:1055-1057.
11. Witte KKA, Desilva R, Chattopadhyay S, et al. Are hematinic deficiencies the cause of anemia in chronic heart failure? Am Heart J. 2004;147:924-930.
12. Cromie N, Lee C, Struthers AD. Anaemia in chronic heart failure: what is its frequency in the UK and its underlying causes? Heart. 2002;87:377-378.
13. Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107:294-299.
14. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37:1775-1780.
15. Macdougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol. 2000;20:375-381.
16. Egrie JC, Dwyer E, Browne JK, et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol. 2003;31:290-299.
17. Locatelli F, Olivares J, Walker R, et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int. 2001;60:741-747.
18. Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002;40:110-118.
19. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase IH trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002;94:1211-1220.
20. Jadoul M, Vanrenterghem Y, Foret M, et al. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant. 2004;19:898-903.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
22. Allon M, Kleinman K, Walczyk M, et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clin Pharmacol Ther. 2002;72:546-555.
23. Wagoner LE, Butler J, Oren R, et al. Anemia is common in patients with heart failure seen in specialty and community cardiology clinics: results from the STAMINA-HFP Registry (Study of Anemia in a Heart Failure Population). J Am Coll Cardiol. 2004;43(Suppl A):217A. [Abstract]
24. Cleland JGF, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Eur Heart J. 2003;24:442-463.
25. Felker GM, Adams KF, Gattis WA, et al. Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol. 2004;44:959-966.
26. Goodkin DA, Gimenez LF, Graber SE, et al. Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: a post hoc analysis. Clin Nephrol. 1999;51:367-372.